Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which demonstrated anticancer activity with a mechanism consistent with inhibition of Aurora kinase."""@en ; dct:identifier "drugbank:DB05198" ; dct:title "CYC116"@en ; adv:Drug ; rdfs:label "CYC116 [drugbank:DB05198]"@en ; rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05198> . }